Advancing vaccine development through green biotechnology

The diseases hepatitis B (HBV) and C (HCV) remain a significant health threat worldwide, causing approximately 1.3 million deaths each year.

Dietary factors influencing GLP-1 secretion: a new perspective in diabetes and obesity treatment

Researchers in The American Journal of Clinical Nutrition review the impact of diet on GLP-1 secretion in metabolic conditions like obesity and type 2 diabetes,

January 17, 2024

Exercise intervention reduces fall risk in elderly women on multiple medications

An exercise intervention aimed at elderly women was successful at reducing falls, especially among those with polypharmacy, a new study from the University of Eastern

March 11, 2025

Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success – Pharmaceutical Technology

According to GlobalData, Novo Nordisk’s Wegovy (semaglutide) (indicated for obesity) and Ozempic are forecast to reach sales of $8.1bn and $2.1bn by 2031, respectively. Credit:

October 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.